US 12,458,637 B2
Targeting WNK1 in blood cancers
Kristian Helin, Copenhagen N (DK); and Karl Agger, Copenhagen N (DK)
Assigned to Københavns Universitet, Copenhagen K (DK)
Appl. No. 17/633,905
Filed by Københavns Universitet, Copenhagen K (DK)
PCT Filed Aug. 11, 2020, PCT No. PCT/EP2020/072514
§ 371(c)(1), (2) Date Feb. 8, 2022,
PCT Pub. No. WO2021/028438, PCT Pub. Date Feb. 18, 2021.
Claims priority of application No. 19191246 (EP), filed on Aug. 12, 2019.
Prior Publication US 2022/0288063 A1, Sep. 15, 2022
Int. Cl. A61K 31/496 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/496 (2013.01) [A61P 35/02 (2018.01)] 8 Claims
 
1. A method of treating a blood cancer in a mammalian subject comprising administering an inhibitor of lysine deficient protein kinase 1 (WNK1) to a mammalian subject in need thereof, wherein the inhibitor of lysine deficient protein kinase 1 (WNK1) is (5-Chloro-2-(2-(methylamino)thiazol-4-yl)-pyridin-4-yl)(4-(4-chlorobenzyl)piperazin-1-yl)methanone) or (5-Chloro-2-(2-((methyl-d3)amino)thiazol-4-yl)-pyridin-4-yl)(4-(4-chlorobenzyl)piperazin-1-yl)methanone).